Literature DB >> 27507851

Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome.

Miao Liu1, Li-Xing Feng1, Peng Sun1, Wang Liu1, Tian Mi1, Min Lei2, Wanying Wu1, Baohong Jiang1, Min Yang1, Lihong Hu3, De-An Guo4, Xuan Liu4,5.   

Abstract

This study compared the sensitivity of human hepatoma Hep3B, SK-HEP-1, SMMC-7721, and BEL-7402 cells to cardiac steroids, including bufalin (BF), a bufalin derivative (BF211), ouabain (OUA), and digitoxin (DIG). Hep3B cells exhibited relatively low sensitivity to cardiac steroids. Expression levels of subunits of Na+/K+-ATPase were high in Hep3B cells. However, colocalization of Na+/K+-ATPase and caveolin was nearly undetectable in Hep3B cells. By using RNA-Seq technology, we found a total of 36 genes to be differentially expressed between Hep3B cells and SK-HEP-1 cells, which are highly sensitive to cardiac steroids. Our bioinformatics analysis determined that these genes were mostly comprised of extracellular space, protein binding, and extracellular region. Among these 36 genes, apolipoprotein E (APOE) played a critical role, as knockdown APOE expression induced colocalization of Na+/K+-ATPase and caveolin and increased sensitivity of Hep3B cells to both proliferation-inhibiting and cytotoxic effects of BF or BF211. Also, the effects of BF on PI3K/AKT/GSK3β and apoptosis signal cascades were enhanced in APOE knockdown cells. The results of our study confirmed the role of Na+/K+-ATPase signalosome in cytotoxicity of cardiac steroids and suggested that APOE regulated the sensitivity of cells to cardiac steroids by affecting formation and function of Na+/K+-ATPase signalosome. In addition, intercellular interaction with high level of Na+/K+-ATPase β1 subunit may be also a factor in the low sensitivity of Hep3B cells to cardiac steroids. Mol Cancer Ther; 15(12); 2955-65. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27507851     DOI: 10.1158/1535-7163.MCT-15-0961

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  4 in total

1.  Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α.

Authors:  Xiao-Ping Chai; Guang-Long Sun; Yan-Fen Fang; Li-Hong Hu; Xuan Liu; Xiong-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

Review 2.  New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin.

Authors:  Chien-Shan Cheng; Jiaqiang Wang; Jie Chen; Kuei Ting Kuo; Jian Tang; Huifeng Gao; Lianyu Chen; Zhen Chen; Zhiqiang Meng
Journal:  Cancer Cell Int       Date:  2019-04-11       Impact factor: 5.722

Review 3.  Apolipoproteins and cancer.

Authors:  Liwen Ren; Jie Yi; Wan Li; Xiangjin Zheng; Jinyi Liu; Jinhua Wang; Guanhua Du
Journal:  Cancer Med       Date:  2019-10-01       Impact factor: 4.452

4.  Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma.

Authors:  Raphael Berges; Emilie Denicolai; Aurélie Tchoghandjian; Nathalie Baeza-Kallee; Stephane Honore; Dominique Figarella-Branger; Diane Braguer
Journal:  Cell Death Dis       Date:  2018-09-24       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.